© 2020 MJH Life Sciences and HCPLive. All rights reserved.
© 2020 MJH Life Sciences™ and HCPLive. All rights reserved.
September 17, 2020
Current therapies focus on relief of symptoms, but there is still an unmet need to address and target the molecular defects of hypertrophic cardiomyopathy.
September 03, 2020
Manan Pareek, MD, PhD gives an overview about what is currently known about COVID-19 and cardiovascular risk.
September 01, 2020
Investigators report on a post-hoc analysis of the EMPA-REG OUTCOME trial that assesses the efficacy of the SGLT-2 inhibitor in patients with obstructive sleep apnea.
These guidelines set by ESC and EAS 2019 established treatment goals for LDL-C, non-HDL-C, and Apo-B in patients at high risk for cardiovascular disease.
The new equation model has shown to be more accurate than the Framingham Lifetime Risk equation and Pooled Cohort Equation.
Post hoc analysis of REAL-CAD shows the cholesterol metric does not serve to inform statin treatment control of coronary artery disease.
The congress president shares her favorite sessions, and ideas to integrate virtual setting successes into next year's meeting.
August 31, 2020
New data shows that high BMI individuals who were in the lowest polygenic score quintile had a 5-fold greater risk of diabetes than those with low BMI and a high polygenic score.
According to late breaking data, younger women exhibit a decreased risk for heart attack mortality due to estrogen’s protective effect
What ESC has learned about the benefits and difficulties of online-only forums.